TLR7激动剂增强人CIK细胞杀伤功能的研究  

TLR7 agonist enhances cytotoxicity of human cytokine-induced killer cells

作　　者：陈艳媛 李旺 魏志璋 王宇环 罗晓玲 高东 

机构地区：[1]深圳市合一康生物科技股份有限公司,518045

出　　处：《免疫学杂志》2016年第7期638-640,共3页Immunological Journal

基　　金：深圳市基础研究项目(JCYJ20130326110139687;CXZZ20140509144527788)

摘　　要：目的研究Toll样受体7（toll-like receptors 7,TLR7）激动剂（Tlr7a）对人细胞因子诱导的杀伤细胞（cytokine-inducedkiller cell,CIK）杀瘤效果的影响。方法采集3名健康志愿者外周血,分离外周血单个核细胞（peripheral blood mononuclear cell,PBMC）,按照常规CIK细胞培养（Control组）或day0额外添加Tlr7a（Tlr7a组）2种方案培养2周。采用细胞计数法检测细胞的增殖效率,流式细胞术检测细胞亚群的比例,CCK-8比色法检测CIK细胞对人红白血病细胞（K562细胞）的杀伤活性。结果与对照比,Tlr7a处理后,总细胞中主要效应细胞CD3^＋CD56^＋双阳细胞占比增加4.1%,分别为（11.9±2.9）%和（16.0±5.8）%。杀伤实验结果显示,当E∶T为20∶1时,2组细胞对K562杀伤率分别为（98.8±4.2）%和（74.4±12.3）%。相比于Control组,Tlr7a组的细胞杀伤功能明显增强（P〈0.05）。结论 TLR7激动剂（Tlr7a）具有增强CIK效应细胞的扩增能力,其刺激后获得的CIK细胞对K562肿瘤细胞的杀伤效果更好。This study performed to investigate the effects of toll-like receptors 7（TLR7） agonist（Tlr7a） oncytotoxicity of human cytokine-induced killer cell（CIK）.Human peripheral blood mononuclear cells（PBMCs） wereisolated from healthy donors（n=3）,and then cultured in routine（group control） or cocultured with Tlr7 a at day 0（group Tlr7a） for two weeks.Cell counter and flow cytometry were used to compare cell amplification efficiency andthe percentage of cell subset.Cytotoxic activity against K562 cell was measured by cell counting kit-8（CCK-8）.The results indicated that the percentage of CD3＋~CD56＋~CIK cells in group Tlr7 a was（16.0±5.8）%,which was higherthan that of the group control（11.9±2.9）%.At the effector/target ratio of 20∶1,the killing rates of group Tlr7a（98.8±4.2）% was significantly higher than that of group control were（74.4±12.3）%（P〈0.05）.Taken together,TLR7 agonist（Tlr7a） can stimulate a higher proportion of CIK cells,and its killing effect on K562 cells is better.

关 键 词：CIK细胞 TOLL样受体 肿瘤 杀伤率 

分 类 号：R730.5[医药卫生—肿瘤]